TAMPA, Fla. — As mounting evidence suggests that the administration of cannabis can reduce the frequency of migraine headaches, Neutra Corp. (OTCQB:NTRR) will explore the promise of advanced cannabinoid delivery technologies to ease migraine sufferers’ pain.
Data published online ahead of print in the journal Pharmacotherapy finds that cannabis administration is clearly associated with decreased migraine frequency. The report comes from investigators at the University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, who assessed cannabis’ effects on monthly migraine frequency in a group of 121 adults. The authors discovered that 85 percent of subjects reported a decrease in migraine frequency, with 12 percent reporting that use of cannabis prior to a migraine’s onset could prevent a headache altogether.
Case reports have previously documented positive results for cannabis in the treatment of migraines, leading scientists to theorize that cannabinoids may have a role to play in migraine regulation.
NTRR is working to devise new cannabinoid delivery technologies in order to help medical cannabis patients treat their migraines more reliably and effectively. In its quest to build a portfolio of wellness-related technology assets ripe for commercialization, NTRR is researching cutting-edge cannabis inhaler technology, as well as a range of cannabis-infused topicals to potentially include lotions, oils and balms.
“Cannabis is used to effectively treat all sorts of maladies, so it only makes sense that consumers are demanding a wide variety of compatible drug delivery methods,” said NTRR CEO Chris Brown. “Inhalers and topical salves could provide superior options to patients suffering from migraines and debilitating issues.”
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Chris Brown, 813-367-2041
President and CEO
Additional information on this topic from NORML:
Study: Marijuana Decreases Migraine Frequency
Aurora, CO: Cannabis administration is associated with decreased migraine headache frequency, according to data published online in the journal Pharmacotherapy.
Investigators at the University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences retrospectively assessed cannabis’ effects on monthly migraine headache frequency in a group of 121 adults. Study participants had a primary diagnosis of migraine headache, had been recommended cannabis by a physician for Scintillating Scotoma and migraine treatment, and had participated in at least one follow up medical visit.
Authors reported that 85 percent of subjects reported a decrease in migraine frequency and 12 percent indicated that the use of cannabis prior to migraine onset would abort headaches.
“Migraine headache frequency decreased from 10.4 to 4.6 headaches per month with the use of medical marijuana,” researchers concluded. “Further research should be performed to determine if there is a preferred delivery method, dose, and strain of medical marijuana for migraine headache therapy as well as potential long-term effects of medical marijuana.”
Although case reports have previously documented the effect of cannabinoids for migraine relief, no prospective trials have yet to evaluate cannabis use in migraine patients. Nonetheless, scientists for some time have theorized that cannabinoids may play a role in migraine regulation. Writing in 2007 in the European Journal of Critical Pharmacology, Italian researchers reported that patients with chronic migraines possessed significantly lower levels of the endogenous cannabinoids anandamide and 2-arachidonylglycerol (2-AG) in their platelets compared to age-matched controls. “These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of chronic migraine and medication-overuse headaches,” they concluded.
For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Effects of medical marijuana on migraine headache frequency in an adult population,” appears online in Pharmacotherapy.